[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100618714":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":27,"locations":33,"responsibleParty":45,"collaborators":24,"id":47,"slug":24,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":24,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":24,"enrollmentInfo":55,"targetDuration":24,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":24,"overallStatus":36,"whyStopped":24,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Huons Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"HUC3-637","EXPERIMENTAL","Dorzolamide, Timolol",[13],"Drug: HUC3-637",{"label":15,"type":16,"description":11,"interventionNames":17},"HUC3-637-R","ACTIVE_COMPARATOR",[18],"Drug: HUC3-637-R",[20,25],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Ophthalmic solution instilled directly into the eye (topical ocular administration)",[9],null,{"type":21,"name":15,"description":22,"armGroupLabels":26,"otherNames":24},[15],[28],{"name":29,"role":30,"phone":31,"phoneExt":24,"email":32},"Rang Lee","CONTACT","07074926091","rlee@huons.com",[34],{"facility":35,"status":36,"city":37,"state":24,"zip":24,"country":38,"countryCode":24,"cosmosGeoPoint":39,"geoPoint":44,"contacts":24},"Kangbuk Samsung Hospital","RECRUITING","Seoul","South Korea",{"type":40,"coordinates":41},"Point",[42,43],126.9784,37.566,{"lat":43,"lon":42},{"type":46,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100618714",false,"NCT07335211","Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension","A Multicenter, Randomized, Single-blind, Active Controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension","Inclusion Criteria:\n\n* Adults aged 19 years and older\n* Participants diagnosed with POAG or OH\n* Have fully explained and understood the study and have voluntarily given written informed consent.\n\nExclusion Criteria:\n\n* Acute or chronic angle-closure glaucoma\n* Congenital glaucoma, secondary glaucoma (open-angle glaucoma)","ALL","19 Years",{"count":56,"type":57},206,"ESTIMATED","INTERVENTIONAL",[60],"PHASE3","A multicenter, randomized, single-blind, active controlled, phase III clinical trial to evaluate the efficacy and safety of HUC3-637 in patients with primary open angle glaucoma or ocular hypertension",[63,64],"Primary Open Angle Glaucoma (POAG)","Ocular Hypertension","2026-01-11",{"date":67,"type":68},"2026-01-13","ACTUAL",{"date":70,"type":57},"2026-01",{"date":72,"type":57},"2027-12",{"name":5,"class":6},1]